Skip to content
lifestyle.the-newshub.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cogent Biosciences, Inc.
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
May 31, 2026
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
May 31, 2026
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
May 29, 2026
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
May 27, 2026
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2026
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
May 25, 2026
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
May 22, 2026
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
May 19, 2026
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
February 28, 2026
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
February 17, 2026
1
2
Next Page
→